Ligand Pharmaceuticals (LGND) EBT Growth (3y) (2013 - 2026)

Ligand Pharmaceuticals (LGND) EBT Growth (3y) (2013 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBT Growth (3y) (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - 9.34%
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 40.43%
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 12.01%
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn -1.05%
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn 86.16%
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Ligand Pharmaceuticals 6.05 Bn 5.27 Bn 48.45 Mn -34.57%

Historic Data

Download Data
DateValue
Mar 31, 2026 -34.57%
Dec 31, 2025 32.99%
Sep 30, 2025 125.22%
Jun 30, 2025 9.02%
Mar 31, 2025 -76.39%
Dec 31, 2024 -61.24%
Sep 30, 2024 -34.17%
Jun 30, 2024 -58.26%
Mar 31, 2024 170.00%
Dec 31, 2023 4.00%
Sep 30, 2023 -1.50%
Jun 30, 2023 -51.69%
Mar 31, 2023 56.40%
Dec 31, 2022 70.46%
Sep 30, 2022 37.89%
Jun 30, 2022 35.37%
Mar 31, 2022 -26.22%
Dec 31, 2021 32.28%
Sep 30, 2021 -42.25%
Jun 30, 2021 -29.63%